Long non-coding RNA in glioma: novel genetic players in temozolomide resistance

Roh, Jungwook; Im, Mijung; Kang, JiHoon; Youn, BuHyun; Kim, Wanyeon

doi:10.1080/19768354.2023.2175497

Cited by 12 publications

(7 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Temozolomide is currently known as an important chemotherapeutic for GBM treatment, but its limitations are highlighted by drug resistance (Chien et al 2021 ; Roh et al 2023 ; Teraiya et al 2023 ). Other treatment methods have been studied, including clinical trials for targeted therapies, such as bevacizumab, which targets VEGF (Fu et al 2023 ) and EGFR (erlotinib, lapatinib, and gefitinib) inhibitors that focus on EGFR , and PI3 K/AKT/mTOR inhibitors aimed at the PI3 K/AKT/mTOR signaling pathway (Pan and Magge 2020 ).…”

Section: Discussionmentioning

confidence: 99%

HSPA5 and FGFR1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacy

Lee,

Park,

Hong

2024

Animal Cells and Systems

View full text Add to dashboard Cite

Tyrosine kinase inhibitors (TKIs) have emerged as a potential treatment strategy for glioblastoma multiforme (GBM). However, their efficacy is limited by various drug resistance mechanisms. To devise more effective treatments for GBM, genetic characteristics must be considered in addition to pre-existing treatments. We performed an integrative analysis with heterogeneous GBM datasets of genomic, transcriptomic, and proteomic data from DepMap, TCGA and CPTAC. We found that poor prognosis was induced by co-upregulation of heat shock protein family A member 5 ( HSPA5 ) and fibroblast growth factor receptor 1 ( FGFR1 ). Co-up regulation of these two genes could regulate the PI3K/AKT pathway. GBM cell lines with co-upregulation of these two genes showed higher drug sensitivity to PI3K inhibitors. In the mesenchymal subtype, the co-upregulation of FGFR1 and HSPA5 resulted in the most malignant subtype of GBM. Furthermore, we found this newly discovered subtype was correlated with homologous recombination deficiency (HRD) In conclusion, we discovered novel druggable candidates within the group exhibiting co-upregulation of these two genes in GBM, suggest potential strategies for combination therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

HSPA5 and FGFR1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacy

Lee,

Park,

Hong

2024

Animal Cells and Systems

View full text Add to dashboard Cite

show abstract

“…They can interact with chromatin-modifying proteins and affect the methylation and acetylation status of histones, thereby regulating gene transcription. LncRNA H19, for instance, has been shown to play a role in the epigenetic silencing of tumor suppressor genes in pediatric gliomas [ 62 ]. LncRNAs can function as ceRNAs (competing endogenous RNAs) by sponging miRNAs and preventing them from binding to their target mRNAs.…”

Section: Lncrnas In Gliomasmentioning

confidence: 99%

Insights into the Role of LncRNAs and miRNAs in Glioma Progression and Their Potential as Novel Therapeutic Targets

Kciuk

Yahya

Mohamed

et al. 2023

Cancers

View full text Add to dashboard Cite

Accumulating evidence supports that both long non-coding and micro RNAs (lncRNAs and miRNAs) are implicated in glioma tumorigenesis and progression. Poor outcome of gliomas has been linked to late-stage diagnosis and mostly ineffectiveness of conventional treatment due to low knowledge about the early stage of gliomas, which are not possible to observe with conventional diagnostic approaches. The past few years witnessed a revolutionary advance in biotechnology and neuroscience with the understanding of tumor-related molecules, including non-coding RNAs that are involved in the angiogenesis and progression of glioma cells and thus are used as prognostic biomarkers as well as novel therapeutic targets. The emerging research on lncRNAs and miRNAs highlights their crucial role in glioma progression, offering new insights into the disease. These non-coding RNAs hold significant potential as novel therapeutic targets, paving the way for innovative treatment approaches against glioma. This review encompasses a comprehensive discussion about the role of lncRNAs and miRNAs in gene regulation that is responsible for the promotion or the inhibition of glioma progression and collects the existing links between these key cancer-related molecules.

show abstract

“…Individuals with GBM have an average overall survival of 15–18 months after diagnosis (Alves et al 2021 ; Wu et al 2021 ). Despite multimodal treatment options like surgery, radiotherapy, and chemotherapy, current approaches have had extremely limited success (Davis 2016 ; Taylor et al 2019 ; Roh et al 2023 ). In recent years, glioma stem cells (GSCs) have been linked to the aggressive characteristics of GBM (Alves et al 2021 ).…”

Section: Introductionmentioning

confidence: 99%

The impact of MEIS1 TALE homeodomain transcription factor knockdown on glioma stem cell growth

Kim,

Batara,

Jeon

et al. 2024

Animal Cells and Systems

View full text Add to dashboard Cite

Myeloid ecotropic virus insertion site 1 ( MEIS1 ) is a HOX co-factor necessary for organ development and normal hematopoiesis. Recently, MEIS1 has been linked to the development and progression of various cancers. However, its role in gliomagenesis particularly on glioma stem cells (GSCs) remains unclear. Here, we demonstrate that MEIS1 is highly upregulated in GSCs compared to normal, and glioma cells and to its differentiated counterparts. Inhibition of MEIS1 expression by shRNA significantly reduced GSC growth in both in vitro and in vivo experiments. On the other hand, integrated transcriptomics analyses of glioma datasets revealed that MEIS1 expression is correlated to cell cycle-related genes. Clinical data analysis revealed that MEIS1 expression is elevated in high-grade gliomas, and patients with high MEIS1 levels have poorer overall survival outcomes. The findings suggest that MEIS1 is a prognostic biomarker for glioma patients and a possible target for developing novel therapeutic strategies against GBM.

show abstract

Long non-coding RNA in glioma: novel genetic players in temozolomide resistance

Cited by 12 publications

References 96 publications

HSPA5 and FGFR1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacy

HSPA5 and FGFR1 genes in the mesenchymal subtype of glioblastoma can improve a treatment efficacy

Insights into the Role of LncRNAs and miRNAs in Glioma Progression and Their Potential as Novel Therapeutic Targets

The impact of MEIS1 TALE homeodomain transcription factor knockdown on glioma stem cell growth

Contact Info

Product

Resources

About